Stock Ratings / Health Care / FLGT / financials

YDES (37) LMRI (58) CSTL (60) TRUP (64) ⌘ Pro Terminal →

Fulgent Genetics Inc. (FLGT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$21.68 +0.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.67

Fulgent Genetics Inc. (FLGT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $596.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $21.67 (-0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FLGT)Realized 20D OHLCV Swing Band: ±9.3%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY FLGT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)

20D Institutional Volume Accumulation (±9.3% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$21.74-8.9% Next Q

Q2 (-2Q)

Grade E$19.81+1.5% Next Q

Q3 (-1Q)

Grade E$20.10+7.9% Next Q

Current

Grade E$21.68-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FLGT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FLGT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.77) and Max Pain ($22.76) forces dealer call-delta covering toward $32.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FLGT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “FLGT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How FLGT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $289.2M

FY24

Rev $283.5M

FY25

Rev $322.7M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$322.7M	40.6%	-28.2%	-$60.5M	-$124.2M	-6.8%
FY 2024	$283.5M	37.8%	-26.1%	-$42.7M	-$19.3M	-5.4%
FY 2023	$289.2M	40.6%	-67.6%	-$167.8M	$27.0M	-6.8%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FLGT)

✓Walkthrough of FLGT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

FLGT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.73%▲ ASCENDING CHANNEL

2026-10-30O $21.50H $21.77L $20.54C $21.68VOL 201.4K

RES: $23.74SUP: $19.64SMA50: $20.77SMA200: $19.37

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FLGT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FLGT Butterfly Map → + Track FLGT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on FLGT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FLGT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for FLGT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FLGT)

Health Care Rank #838 of 1016 ⚔️ YDES vs FLGT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FLGT vs. YDES, LMRI, CSTL, TRUP)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Fulgent Genetics Inc. (FLGT) ranks #838 by composite RQD confidence (34/100, grade E) and #421 by equity capitalization ($596.5M). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while TRUP leads on capital efficiency and profitability with 3.1% ROIC and 16.1% gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with FLGT at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
FLGT ACTIVE Fulgent Genetics Inc.	E	34/100	—	40.6%	-6.8%	+0.74%	$596.5M	Benchmark Subject
YDES YD Bio Limited	D-	37/100	—	28.1%	-20.0%	-6.53%	$415.8M	/ydes-vs-flgt →
LMRI Lumexa Imaging Holdings Inc.	D+	58/100	—	—	—	+0.95%	$1.13B	/lmri-vs-flgt →
CSTL Castle Biosciences Inc.	C-	60/100	—	79.4%	-9.3%	+4.99%	$1.18B	/cstl-vs-flgt →
TRUP Trupanion Inc.	C	64/100	68.2x	16.1%	3.1%	+2.27%	$1.32B	/trup-vs-flgt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674930

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulgent Genetics Inc. (FLGT) reported GAAP revenue of $322.7M (+13.8% vs. FY2024 revenue of $283.5M , and +11.6% cumulative change since FY2023) , GAAP net income of -$60.5M, operating cash flow of -$101.6M, and free cash flow of -$124.2M (-545.1% YoY). On the balance sheet, FLGT closed FY2025 with $1.21B in total assets against $0 in total debt (Altman Z-Score: 4.44, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$322.7M	-$60.5M	-$101.6M	-$124.2M	$1.21B	—
FY2024 (FY)	2024-12-31	$283.5M	-$42.7M	$21.1M	-$19.3M	$1.22B	—
FY2023 (FY)	2023-12-31	$289.2M	-$167.8M	$27.0M	$27.0M	—	—

3. FLGT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FLGT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Fulgent Genetics Inc. (NASDAQ: FLGT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $21.68 (+0.74% 1D, market cap $596.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FLGT ranks #838 in composite RQD confidence.

How does FLGT compare to YDES and LMRI in the Health Care sector?

Within the Health Care sector (Medical Specialities), FLGT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 40.6%, and ROIC of -6.8%. By comparison, YDES (YD Bio Limited) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.0%, cap $415.8M) and LMRI (Lumexa Imaging Holdings Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while TRUP leads on capital efficiency (3.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FLGT?

Per FLGT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674930), Fulgent Genetics Inc. generated $322.7M in revenue (+13.8% YoY), -$60.5M in net income, and -$124.2M in free cash flow against $1.21B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FLGT trading relative to its 50-day, 200-day, and 52-week technical levels?

FLGT last traded at $21.68 (+0.74% on volume of 210,296 shares), positioning the stock +4.38% above its 50-day simple moving average ($20.77) and +11.93% above its 200-day simple moving average ($19.37). Across its 52-week range of $13.46 to $31.04, FLGT sits at the 46.8% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($19.66 to $23.70).

FLGT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Fulgent Genetics Inc. (FLGT)?

In FY 2025 (10-K), FLGT converted $322.7M of revenue into a 40.6% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: FLGT RQD Cockpit FLGT 12M Forecast FLGT Earnings & Move FLGT Dividends & DRIP FLGT Insiders & 13F FLGT Whale Options FLGT Profit Sankey FLGT News & Why